Focus: Rare Diseases including Neuromyelitis Optica Spectrum Disorder (NMOSD).
Horizon Therapeutics, now a part of Amgen, is a global biotechnology company focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare diseases.
